SetPoint Medical, a clinical-stage healthcare company focused on chronic autoimmune diseases, has received the prestigious EULAR Abstract Award in the Clinical Research category for its groundbreaking RESET-RA study. The European Alliance of Associations for Rheumatology (EULAR) 2025 Congress recognized the company's abstract OP0190, titled "Neuroimmune Modulation for Treatment of Rheumatoid Arthritis in Adults with Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 weeks from a Randomized, Sham-Controlled, Double-Blind Study (RESET-RA Study)."
First-of-Its-Kind Clinical Trial
The RESET-RA study represents a significant milestone as the first randomized, sham-controlled, double-blind trial to positively demonstrate the clinical potential of neuroimmune modulation for treating rheumatoid arthritis. This achievement marks a notable advancement in exploring alternative therapeutic approaches for patients who have experienced inadequate response or intolerance to conventional biological or targeted synthetic disease-modifying antirheumatic drugs (DMARDs).
"We are honored to receive this prestigious award from EULAR, which recognizes the strength and promise of our clinical research using neuroimmune modulation for the treatment of rheumatoid arthritis," said David Chernoff, M.D., Chief Medical Officer of SetPoint Medical. "This recognition reflects the dedication of our team to progressing the clinical development of the SetPoint System, and its potential to advance the care of individuals living with rheumatoid arthritis."
Novel Therapeutic Platform
SetPoint Medical's platform technology operates through a unique mechanism designed to stimulate the vagus nerve to activate neuroimmune pathways, producing a systemic anti-inflammatory and immune-restorative effect. This approach represents a departure from traditional pharmaceutical interventions, potentially offering patients and healthcare providers a treatment alternative with less risk and cost compared to conventional drug therapy.
The SetPoint System is being developed not only for rheumatoid arthritis but also for multiple sclerosis, inflammatory bowel disease, and other chronic autoimmune conditions, suggesting broad therapeutic potential across the autoimmune disease spectrum.
Clinical Presentation and Recognition
EULAR bestows Abstract Awards to the highest-scoring abstracts submitted to its Annual European Congress in basic science or clinical research categories. Winners are selected by the EULAR Scientific Program Committee based on the quality of the abstracts' scientific content, underscoring the significance of SetPoint Medical's research findings.
Dr. Chernoff will present the 12- and 24-week results from the RESET-RA study in an oral abstract presentation on Thursday, June 12, 2025, at 10:30 - 10:40 AM CEST in Room A2 during the Clinical Abstract Session on Management strategies in Rheumatoid Arthritis. John Tesser, MD, FACP, FACR, MACR of Arizona Arthritis & Rheumatology Associates in Phoenix, Arizona, serves as the principal rheumatology investigator of the study.
The presentation will highlight both safety and efficacy results of the SetPoint System through 24 weeks, providing the medical community with comprehensive data on this novel neuroimmune modulation approach for rheumatoid arthritis treatment.
